Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 11 2025
0mins
Source: Newsfilter
Appointment of Chief Medical Officer: Lycia Therapeutics has appointed Dr. Chin Lee as its chief medical officer, who will oversee clinical and regulatory functions as the company advances its LYTAC-based therapies targeting autoimmune and inflammatory diseases.
Innovative Treatment Programs: The company is developing two lead programs, LCA-0061 for IgE-mediated diseases and LCA-0321 for Graves' disease, which aim to provide more effective treatments by selectively degrading pathogenic proteins associated with these conditions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
